Steven Cohen Uro Gen Pharma Ltd. Transaction History

Point72 Asset Management, L.P.

$36 Billion
Q2 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 2,449,277 shares of URGN stock, worth $29.6 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

2,449,277

Previous 2,449,277 -0.0%

Holding current value

$29.6 Million

Previous $41.1 Million -0.0%

% of portfolio

0.11%

Previous 0.11%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$12.72 - $19.2 $17 Million - $25.7 Million	1,337,257 Added 120.25%	2,449,277 $41.1 Million
Q1 2024 May 15, 2024	BUY	$13.81 - $19.33 $13.6 Million - $19.1 Million	986,020 Added 782.56%	1,112,020 $16.7 Million
Q4 2023 Feb 14, 2024	SELL	$10.87 - $15.93 $888,437 - $1.3 Million	-81,733 Reduced 39.35%	126,000 $1.89 Million
Q3 2023 Nov 14, 2023	BUY	$8.84 - $22.64 $1.84 Million - $4.7 Million	207,733 New	207,733 $2.91 Million
Q1 2020 May 15, 2020	SELL	$13.68 - $34.6 $3.04 Million - $7.68 Million	-222,024 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$21.11 - $34.86 $3.47 Million - $5.72 Million	164,222 Added 284.11%	222,024 $7.41 Million
Q3 2019 Nov 15, 2019	BUY	$23.83 - $36.44 $6,910 - $10,567	290 Added 0.5%	57,802 $1.38 Million
Q2 2019 Aug 14, 2019	SELL	$32.75 - $40.35 $6.75 Million - $8.32 Million	-206,087 Reduced 78.18%	57,512 $2.07 Million
Q1 2019 May 15, 2019	BUY	$35.47 - $54.55 $7.04 Million - $10.8 Million	198,599 Added 305.54%	263,599 $9.74 Million
Q4 2018 Feb 14, 2019	BUY	$38.35 - $50.39 $496,785 - $652,752	12,954 Added 24.89%	65,000 $2.8 Million
Q3 2018 Nov 14, 2018	BUY	$41.65 - $51.7 $2.17 Million - $2.69 Million	52,046 New	52,046 $2.46 Million

Others Institutions Holding URGN

# of Institutions

122

Shares Held

39.6M

Call Options Held

158K

Put Options Held

161K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $275M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account